PFI
This article was originally published in The Tan Sheet
Executive Summary
Private labeler plans to launch Ibuprofen Cold & Sinus, comparable to Whitehall-Robins' Advil Cold & Sinus, by year-end. Pharmaceutical Formulations, Inc. is awaiting FDA approval of its ANDA for the ibuprofen/pseudoephedrine combo, which has already lost market exclusivity. Perrigo also plans to launch a generic version of the product before next year's cough/cold season, the firm says